Showing posts with label 500 BEST PML STORIES & STUDIES. Show all posts
Showing posts with label 500 BEST PML STORIES & STUDIES. Show all posts

Thursday, April 7

Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy (PML): Risks and Detection: VIDEO























Fred Lublin, MD, explains that prior to the use of Tysabri (natalizumab), progressive multifocal leukoencephalopathy (PML) had never been observed in patients with multiple sclerosis (MS). Providing accurate figures about the risk of PML to patients who may be or are being treated with natalizumab iscritically important in makingthe best treatment choices. PML is not as severe and lethal in the setting of MS as in other diseases, such as HIV. Still, he adds,PML often leaves individuals left with some kind of disability, and the mortality rate in MS is about 20%.

Thursday, July 2

Researchers Suggest Short Transition Period Between Tysabri (Natalizumab) and Gilenya (Fingolimod) Therapies to Control RRMS Disease Activity




























An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from natalizumab to fingolimod therapy. The study was recently published in the journal Neurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.”

Friday, May 16

S*** NHS England green-lights switch from Tysabri to Gilenya in MSers at high-risk of PML

NHS England green-lights switch from natalizumab to fingolimod in MSers at high-risk of PML#MSBlog #MSResearch #ClinicSpeak

Interferon-beta, GA or steroids not good enough to prevent rebound activity #MSBlog #MSResearch #ClinicSpeak

"The study below confirms what we already know; stopping natalizumab leads to rebound in MS disease activity. Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound. In comparison, a higher-efficacy drug such as fingolimod appears to prevent this rebound provided it is started within 4 weeks after the last natalizumab infusion."

"Most MSers stopping natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod. I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be  working; touch wood we have had no cases of carry-over PML."

"In clinic last week someone asked me about switching from natalizumab to alemtuzumab? Alemtuzumab is an induction agent and hence you can't reverse its action. If you developed carry-over PML after switching from natalizumab to alemtuzumab the chances are you will die from the PML as your immune system will not be able to respond quickly enough to clear the virus. Post alemtuzumab it takes over 3 months for your immune system to recover. For this reason I am telling my patients that it will be much safer for them to switch to a maintenance agent, for example fingolimod, for several months or years, before switching to alemtuzumab post-natalizumab. The latter advice is not evidence-based and is unlikely to become evidence-based in the future; this advice is based in scientific principles on how the different DMTs affect your immune system."

"For UK MSers who read this blog we have finally been given the green-light by NHS England to switch MSers at high-risk of PML on natalizumab to fingolimod, who have never been treated with interferon-beta or GA in the past.


Epub: Fox et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.Neurology. 2014 Mar.

OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.

METHODS: Eligible MSers were relapse-free through the prior year on natalizumab and had no gadolinium-enhancing lesions on screening brain MRI. MSers were randomized 1:1:2 to continue natalizumab, to switch to placebo, or to receive alternative immunomodulatory therapy (other therapies: IM interferon β-1a [IM IFN-β-1a], glatiramer acetate [GA], or methylprednisolone [MP]). During the 24-week randomized treatment period, MSers underwent clinical and MRI assessments every 4 weeks.

CONCLUSIONS: MRI and clinical disease activity recurred in some patients during natalizumab interruption, despite use of other therapies.

CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for MSers with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab. 

http://multiple-sclerosis-research.blogspot.com/2014/04/clinic-speak-what-happens-when-you-stop.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+blogspot%2FWvYVL+%28Multiple+Sclerosis+Research%29

STUDY: Tysabri (Natalizumab) to Gilenya (fingolimod) washout in patients at risk of PML

Upon withdrawing natalizumab, resumption of disease activity was soon observed, beginning 3–4 months after the last dose of natalizumab

BREAKING NEWS ON PML: FDA probes brain infection in patient with MS drug PML

US FDA raised an alert in Europe after emergence of a case of progressive multifocal leukoencephalopathy (PML), following the administration of Novartis multiple sclerosis drug Gilenya
FDA investigates multifocal leukoencephalopathy (PML) in patient on Novartis multiple sclerosis drug Gilenya

HERE'S A NEW EDITORIAL ABOUT TYSABRI AND THE PML PROBLEM FOR MSers NEEDING TO QUIT TYSABRI

Tysabri/Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Gilenya leads to rare disease in patient

Jayce Parente, Columnist, MSnewsChannel.com


Jayce Parente,
Columnist,
MSnewsChannel.com
AM I DYING? I JUST STOPPED TAKING TYSABRI!

Am I ok?
Are these MS symptoms?

Are they the potentially lethal PML symptoms? 


I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.

I know you're gonna say call my "Care Team" but what good is that when they are going to give me a script for a blood test in which it will take me a few days until I can have blood drawn only to wait a few days to get the results when I'm "supposed" to act QUICKLY?

So let me get this straight? I've taken a drug for 2 years that has been linked to causing progressive multifocal leukoencephalopathy (PML). I just stopped taking this drug and am currently detoxing from it.

I also have started to generate more intense symptoms SINCE stopping this drug. Are these MS symptoms?

Are they the potentially lethal PML symptoms?

I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.

Well, identical with the exception of death or increased likelihood of seizures.
I've also been told if I suspect PML it is VERY important to respond quickly so a plasma exchange can be performed.

So, basically, am I supposed to wait for a seizure and I'm on the floor swallowing my tongue to figure out whether I'm having an MS or PML seizure?

So how do I tell?


Any of you guys have any ideas?

Since stopping the Tysabri I've been steadily degrading and gotten MUCH worse to a point I've been embarrassing myself

Update

MSers STOPPING TYSABRI DO IT BECAUSE THEY ARE AT HIGH-RISK OF DEVELOPING PML....

BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY

GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION



"The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity.

Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.

Dr Gavin Giovannoni
In comparison, a higher-efficacy drug such as Gilenya/fingolimod appears to prevent this rebound provided it is started within 4 weeks after the last Tysabri/natalizumab infusion."

"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod.

I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be  working; touch wood we have had no cases of carry-over PML."
SHARE THIS BY CLICKING TINY ENVELOPE BELOW

Clinicians prescribing Tysabri/natalizumab for MS patients who are JC virus serum antibody–positive need to know about this progressive ataxia with cerebellar atrophy syndrome


Tysabri to Gilenya washout in patients at risk of PML: When good intentions yield bad outcomes.

STUDY: Benefit of Additional Screening for PML (Progressive Multifocal Leukoencephalopathy) in MSers Taking Tysabri (Natalizumab): A Decision Analysis